DDInter758 DDInter154
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Clemastine {u} (Compound) resembles {v} (Compound) Azelastine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Azelastine
Fluoxetine {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Azelastine
Fluoxetine {u} (Compound) downregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Azelastine
Fluoxetine {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Azelastine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Azelastine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Meclizine
Meclizine {u} (Compound) resembles {v} (Compound) Azelastine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) EPCAM
EPCAM {u} (Gene) is upregulated by {v} (Compound) Azelastine
Fluoxetine {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is regulated by {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Azelastine
Fluoxetine {u} (Compound) downregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is regulated by {v} (Gene) RPP38
RPP38 {u} (Gene) is upregulated by {v} (Compound) Azelastine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Azelastine (Compound)
Fluoxetine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Azelastine (Compound)
Fluoxetine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Azelastine (Compound)
Fluoxetine (Compound) downregulates GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Azelastine (Compound)
Fluoxetine (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Azelastine (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine and Loxapine (Compound) resembles Azelastine (Compound)
Fluoxetine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Meclizine (Compound) and Meclizine (Compound) resembles Azelastine (Compound)
Fluoxetine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates EPCAM (Gene) and EPCAM (Gene) is upregulated by Azelastine (Compound)
Fluoxetine (Compound) upregulates MAL (Gene) and MAL (Gene) is regulated by CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Azelastine (Compound)
Fluoxetine (Compound) downregulates GTPBP8 (Gene) and GTPBP8 (Gene) is regulated by RPP38 (Gene) and RPP38 (Gene) is upregulated by Azelastine (Compound)